IP Verse

Methods Of Treating Heart Failure With Reduced Ejection Fraction With Dapagliflozin

Patent No. EP4021507 (titled "Methods Of Treating Heart Failure With Reduced Ejection Fraction With Dapagliflozin") was filed by Astrazeneca on Mar 9, 2020. The application was issued on Jul 1, 2026.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BUSSE & BUSSEJul 1, 2026BUSSE & BUSSE
AWA DENMARKJul 1, 2026AWA DENMARK
GENERICS UKJul 1, 2026ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4021507

ASTRAZENECA
Application Number
EP20710490A
Filing Date
Mar 9, 2020
Status
Granted And Under Opposition
May 29, 2026
Publication Date
Jul 1, 2026
External Links
Slate, Register , Google Patents